WINTWINDTREE THERAPEUTICS INC /DE/

Nasdaq windtreetx.com


$ 5.24 $ 0.16 (3.15 %)    

Friday, 26-Apr-2024 15:41:38 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 5.23
$ 5.06
$ 5.22 x 100
$ 0.00 x 0
$ 5.06 - $ 5.24
$ 4.78 - $ 35.10
28,473
na
nm
$ 0.93
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-16-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-07-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-31-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 05-05-2022 03-31-2022 10-Q
9 03-31-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-05-2021 06-30-2021 10-Q
12 05-13-2021 03-31-2021 10-Q
13 03-29-2021 12-31-2020 10-K
14 11-16-2020 09-30-2020 10-Q
15 08-14-2020 06-30-2020 10-Q
16 05-13-2020 03-31-2020 10-Q
17 04-03-2020 12-31-2019 10-K
18 11-14-2019 09-30-2019 10-Q
19 08-14-2019 06-30-2019 10-Q
20 05-20-2019 03-31-2019 10-Q
21 04-16-2019 12-31-2018 10-K
22 11-14-2018 09-30-2018 10-Q
23 08-14-2018 06-30-2018 10-Q
24 05-21-2018 03-31-2018 10-Q
25 04-17-2018 12-31-2017 10-K
26 11-14-2017 09-30-2017 10-Q
27 08-21-2017 06-30-2017 10-Q
28 05-15-2017 03-31-2017 10-Q
29 03-31-2017 12-31-2016 10-K
30 11-14-2016 09-30-2016 10-Q
31 08-10-2016 06-30-2016 10-Q
32 05-12-2016 03-31-2016 10-Q
33 03-29-2016 12-31-2015 10-K
34 11-05-2015 09-30-2015 10-Q
35 08-10-2015 06-30-2015 10-Q
36 05-11-2015 03-31-2015 10-Q
37 03-16-2015 12-31-2014 10-K
38 11-07-2014 09-30-2014 10-Q
39 08-07-2014 06-30-2014 10-Q
40 05-12-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-windtree-therapeutics-wint-stock-is-getting-hammered

Windtree Therapeutics shares are trading lower by 30% during Thursday's session. The company announced it approved a 1-for-...

 windtree-therapeutics-q4-2023-gaap-eps-095-misses-094-estimate

Windtree Therapeutics (NASDAQ:WINT) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate ...

 windtree-enter-asset-purchase-agreement-with-varian-biopharmaceuticals-to-acquire-certain-of-its-assets-including-a-proprietary-atypical-protein-kinase-c-iota-inhibitor

The Company also completed a $1.5 million convertible note bridge financing. With successful development, the Company would pay...

 windtree-therapeutics-eliminates-15m-contingent-liability-to-deerfield-management-company

No Significant Debt On The Balance Sheet And Increased Shareholder Equity Ahead Of Windtree's Anticipated Later-Stage Clini...

 windtree-eliminates-15m-contingent-liability-to-deerfield-management-company

Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on ...

 windtree-therapeutics-to-develop-and-commercialize-drug-candidates-in-china-to-receive-up-to-1381m-in-payments-upon-achievement-of-certain-milestones-and-up-yo-low-double-digit-royalties

The deal supports Windtree's pipeline treatments for acute heart failure and cardiogenic shock and has the potential to pro...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION